DE69523038D1 - Verfahren zur herstellung von hiv proteasinhibitoren - Google Patents

Verfahren zur herstellung von hiv proteasinhibitoren

Info

Publication number
DE69523038D1
DE69523038D1 DE69523038T DE69523038T DE69523038D1 DE 69523038 D1 DE69523038 D1 DE 69523038D1 DE 69523038 T DE69523038 T DE 69523038T DE 69523038 T DE69523038 T DE 69523038T DE 69523038 D1 DE69523038 D1 DE 69523038D1
Authority
DE
Germany
Prior art keywords
piperazine
proteasinhibitors
optically pure
derivatives
enriched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69523038T
Other languages
English (en)
Other versions
DE69523038T2 (de
Inventor
Kai Rossen
David Askin
Paul Reider
J Varsolona
Ralph Volante
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE69523038D1 publication Critical patent/DE69523038D1/de
Application granted granted Critical
Publication of DE69523038T2 publication Critical patent/DE69523038T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Catalysts (AREA)
  • Cephalosporin Compounds (AREA)
DE69523038T 1994-02-04 1995-01-30 Verfahren zur herstellung von hiv proteasinhibitoren Expired - Fee Related DE69523038T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19291694A 1994-02-04 1994-02-04
PCT/US1995/001232 WO1995021162A1 (en) 1994-02-04 1995-01-30 Process for making hiv protease inhibitors

Publications (2)

Publication Number Publication Date
DE69523038D1 true DE69523038D1 (de) 2001-11-08
DE69523038T2 DE69523038T2 (de) 2002-06-06

Family

ID=22711555

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69523038T Expired - Fee Related DE69523038T2 (de) 1994-02-04 1995-01-30 Verfahren zur herstellung von hiv proteasinhibitoren

Country Status (20)

Country Link
US (1) US5663341A (de)
EP (1) EP0741712B1 (de)
JP (1) JPH09508628A (de)
KR (1) KR100337579B1 (de)
AT (1) ATE206407T1 (de)
AU (1) AU691878B2 (de)
BR (1) BR9506727A (de)
CA (1) CA2180947A1 (de)
CZ (1) CZ291774B6 (de)
DE (1) DE69523038T2 (de)
ES (1) ES2161863T3 (de)
FI (1) FI112218B (de)
HU (1) HUT76303A (de)
NZ (1) NZ279734A (de)
RO (1) RO118292B1 (de)
RU (1) RU2135482C1 (de)
SK (1) SK281861B6 (de)
TW (1) TW472047B (de)
UA (1) UA46730C2 (de)
WO (1) WO1995021162A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110255A (en) * 1993-07-16 1998-12-06 Merck & Co Inc Creation and resolution of 2 tert-butylcarboxamidopiprazine
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
DE69527683T2 (de) * 1994-04-22 2003-04-10 Koei Chemical Co Verfahren zur herstellung von optisch aktivem n-tert-butyl-2-piperazincarboxamidamid
ES2116029T3 (es) * 1994-11-04 1998-07-01 Yamakawa Chemical Ind Procedimiento para preparar derivados de piperazina opticamente activos e intermedios para prepararlos.
AU4538296A (en) * 1995-01-23 1996-08-14 Lonza A.G. Process for the production of 1,4,5,6-tetrahydropyrazine-2-carboxylic acid amides
US5618937A (en) * 1995-03-15 1997-04-08 Merck & Co., Inc. Process to make HIV protease inhibitor from (2S)-4-picolyl-2-piperazine-t-butylcarboxamide
US5612484A (en) * 1995-05-18 1997-03-18 Merck & Co., Inc. Process for making HIV protease inhibitors
DE19536658C2 (de) * 1995-09-30 1998-02-19 Degussa Verfahren zur kontinuierlichen Herstellung von basischen, cyclischen, optisch aktiven alpha-Aminosäuren
CA2201218C (en) * 1996-04-23 2004-09-28 Rudolf Fuchs Process for the preparation of optically active piperazine-2-carboxylic acid derivatives
EP1592389B1 (de) 2003-02-14 2009-04-22 Laboratoires Serono SA Derivate von piperazine-2-carboxamide
GB0314260D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB604185A (en) * 1940-08-08 1948-06-30 Arthur Mandl Improvements in electric rectifier systems used in power or control systems such as for follow-up systems
US3692775A (en) * 1969-03-17 1972-09-19 Allied Chem Racemization of d-or l-{60 -amino-caprolactam in the presence of metal ions
US3852351A (en) * 1972-10-02 1974-12-03 Fmc Corp Chlorination of acetoacetamides
JPH01117869A (ja) * 1987-10-30 1989-05-10 Hokuriku Seiyaku Co Ltd ２−アミノメチルピペラジン誘導体
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
ATE163926T1 (de) * 1991-11-08 1998-03-15 Merck & Co Inc Hiv-protease-inhibitoren verwendbar in der aids- behandlung
MX9308016A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.

Also Published As

Publication number Publication date
KR100337579B1 (ko) 2002-11-13
FI112218B (fi) 2003-11-14
MX9603218A (es) 1997-07-31
RU2135482C1 (ru) 1999-08-27
CZ227296A3 (en) 1997-01-15
EP0741712B1 (de) 2001-10-04
FI963054A (fi) 1996-08-01
FI963054A0 (fi) 1996-08-01
AU1696795A (en) 1995-08-21
ES2161863T3 (es) 2001-12-16
EP0741712A1 (de) 1996-11-13
TW472047B (en) 2002-01-11
CA2180947A1 (en) 1995-08-10
RO118292B1 (ro) 2003-04-30
HU9602143D0 (en) 1996-09-30
WO1995021162A1 (en) 1995-08-10
HUT76303A (en) 1997-07-28
UA46730C2 (uk) 2002-06-17
NZ279734A (en) 1998-05-27
AU691878B2 (en) 1998-05-28
CZ291774B6 (cs) 2003-05-14
SK281861B6 (sk) 2001-08-06
BR9506727A (pt) 1997-09-23
SK100696A3 (en) 1997-03-05
US5663341A (en) 1997-09-02
ATE206407T1 (de) 2001-10-15
DE69523038T2 (de) 2002-06-06
JPH09508628A (ja) 1997-09-02

Similar Documents

Publication Publication Date Title
DE69505190T2 (de) Verfahren zur Herstellung von hochreiner Essigsäure
ATE348814T1 (de) Verfahren zur herstellung von chinolinderivaten
ATE188707T1 (de) Verfahren zur herstellung von alanylglutamin
DE69523038T2 (de) Verfahren zur herstellung von hiv proteasinhibitoren
DE69403210T3 (de) Verfahren zur herstellung von n-acetylneuraminsäure
ATE200079T1 (de) Verfahren zur herstellung von hiv-proteasehemmern
ATE233249T1 (de) Verfahren zur herstellung von hiv protease inhibitoren
DE69424899T2 (de) Verfahren zur Herstellung von Essigsäure
DE60012165D1 (de) Verfahren zur herstellung von alendron-säure
DE60039299D1 (de) Verfahren zur herstellung von optisch aktiven azetidin-2-carbonsäuren
DE60039533D1 (de) Verbessertes verfahren zur herstellung von 2s,3s-n-isobutyl-n-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamid hydrochlorid und anderen derivaten von 2-hydroxy-1,3-diamin
ATE402940T1 (de) Verfahren zur herstellung von 3-cephem- verbindungen
DE69819538D1 (de) Verfahren zur verbesserung der optischen reinheit von 2r-[1-hydroxy-1-trifluormethyl-3-cyclopropylpropyn-2-yl]-4-chloranilin
DE69821763D1 (de) Verfahren zur herstellung von 2-alkylthio-substituierten benzoesäurederivaten
ATE301637T1 (de) Verfahren zur herstellung von n-geschützten azetidin-2-carbonsäuren
ATE193280T1 (de) Verfahren zur herstellung von beta-amino-alpha- hydroxycarbonsäuren und deren derivaten
ATE200776T1 (de) Verfahren zur herstellung von 2,4,5-tribrompyrrol-3-carbonitril
ATE159519T1 (de) Verfahren zur herstellung von n-phenyl-n-(4- piperidinyl)amid-derivaten
ATE175199T1 (de) Verfahren zur herstellung von 2-substituierten 5- chlorimidazol-4-carbaldehyden
ATE161822T1 (de) Verfahren zur herstellung von (s)-4-aminohepta- 5,6-diencarbon-säure und intermediate
DE69416117D1 (de) Verfahren zur herstellung von kondensierten carbapenemderivaten
ATE179417T1 (de) Glyceraldehyd-3-pentanid und verfahren zu ihrer herstellung
DE59506734D1 (de) Verfahren zur herstellung n-z-geschützter n-alkylierter aminosäuren
ATE174965T1 (de) Verfahren zur herstellung von halogenierten hydroxyphenylessigsäuren
ATA906094A (de) Verfahren zur herstellung von 3,4-diaryl-5-isoxazolylessigsäurederivaten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee